TAMs may help predict response to PD-1 inhibitors in metastatic clear cell kidney cancer, Dr. Berkay Simsek reported at the 2025 Kidney Cancer Summit.

A new study by Greek-born Costas Arvanitis introduces a research technique to improve cancer diagnosis and treatment.

The immune system is a major determinant of how patients respond to standard treatments for ovarian cancer, the leading cause ...

Researchers have identified how cancer cells exploit ordinary metabolic processes to manipulate immune cells, supporting ...

New therapies harness the body’s cancer-fighting powers, but they don't work for everyone. UChicago experts aim to change ...

Lactic acid (LA) has transitioned from being perceived as a mere glycolytic waste product to a pivotal regulator of ...

T cell senescence occurs in the TME, affecting cancer prognosis and immunotherapy efficacy. The TME induces T cell senescence ...

Presentation to include the first full pharmacokinetic and pharmacodynamic (PK/PD) data from the BEXMAB study; supports bexmarilimab's advancement into Phase III TURKU, FI / ACCESS Newswire / July 30, ...

(Nasdaq: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that the first patient has been dosed in the pivotal Phase 3 OVATION 3 Study ...